BioPharmSignal logoBioPharmSignal

Biotech News

Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Lineage Cell Therapeutics (LCTX)Lineage Cell TherapeuticsEarnings

Positive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen®) Featured at Retinal Therapeutics Innovation Summit 2026 Launched New Corneal Endothelial Disease Cell Therapy Program Met First Milestone with AlloSCOPE™ 5D Manufacturing Initiative Treated Second Chronic SCI Patient in OPC1 DOSED Device

Related news

LCTXLineage Cell Therapeutics2026-05-05 12:00 EST

Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026

LCTXLineage Cell Therapeutics2026-08-06 20:01 EST

Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

LENZLenz Therapeutics Inc2026-05-11 20:05 EST

LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

LENZLenz Therapeutics Inc2026-05-04 12:00 EST

LENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor Conference

OTLKOutlook2026-08-06 12:45 EST

Outlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and Webcast on August 14, 2026

OTLKOutlook2026-05-15 20:05 EST

Outlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update

BLTEBelite Bio2026-05-20 10:00 EST

Belite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update

MGTXMeiraGTx2026-05-14 12:00 EST

MeiraGTx Reports First Quarter 2026 Financial and Operational Results

PRQRProQR Therapeutics2026-05-12 11:00 EST

ProQR Announces First Quarter 2026 Operating and Financial Results

EYPTEyePoint Pharmaceuticals2026-05-06 11:00 EST

EyePoint Reports First Quarter 2026 Financial Results and Highlights Recent Corporate Developments

View all latest news

Lineage Cell Therapeutics

Pluripotent Cell Therapy Company Lineage Cell Therapeutics develops allogeneic, off-the-shelf cell replacements using its AlloSCOPE pluripotent stem-cell engineering and manufacturing platform. OpRegen RG6501, formerly OpRegen, is a retinal pigment epithelium cell replacement therapy partnered with Roche and Genentech for geographic...

Recent company news

LCTXLineage Cell Therapeutics2026-08-06 20:01 EST

Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

LCTXLineage Cell Therapeutics2026-07-30 12:00 EST

Lineage Cell Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026

LCTXLineage Cell Therapeutics2026-07-13 12:00 EST

Lineage Provides Update on COR1 Cell Therapy Program for Corneal Endothelial Disease

LCTXLineage Cell Therapeutics2026-07-06 12:00 EST

Lineage Cell Therapeutics to Present at B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit

LCTXLineage Cell Therapeutics2026-05-12 20:01 EST

Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Stock data

Close
1.13 USD
Market cap
301.65M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States